Zydus Cadila secures USFDA okay for Nelarabine Injection in US
Ahmedabad: Drugmaker, Zydus Cadila, today announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Nelarabine Injection 250MG/50ML in the United States (US RLD: Arranon).
Zydus Pharmaceuticals USA Inc (Zydus) was granted a Competitive Generic Therapy (CGT) designation for Nelarabine Injection, 250 mg/50 mL (5 mg/mL), Single-Dose Vial. Zydus is the "first approved applicant" for Nelarabine Injection, 250 mg/50 mL (5 mg/mL), Single-Dose Vial, as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act.
Therefore, with this approval, Zydus is eligible for 180 days of CGT exclusivity for Nelarabine Injection, 250 mg/50 mL (5 mg/mL), Single-Dose Vial, under section 505(j)(5)(B)(v) of the FD&C Act.
This medication is a chemotherapy drug and used to treat certain types of leukemia and lymphoma by slowing or stopping the growth of cancer cells. Nelarabine is in a class of medications called antimetabolites.
The drug is manufactured at the group's injection manufacturing facility, Alidac plant in Ahmedabad and shall be launched commercially within the US market immediately.
Speaking on the development, Dr. Sharvil Patel, Managing Director, Cadila Healthcare Ltd., said, "This FDA approval of Nelarabine Injection underlines our long-term commitment to patients of providing them access to affordable generics. This approval builds on our proven track-record of successfully commercializing and gaining meaningful market share in complex generics products. We have created a diversified portfolio of more than 50 filed complex ANDAs and will continue to focus on complex generic products as we continue to explore opportunities to grow our US business."
Nelarabine Injection had annual sales of approximately $34.5 million in the United States according to IQVIA data (September 2021).
Zydus, in addition to their complex injectable products, has created an industry leading portfolio of difficult to develop oral solids, drug device combinations, topicals, and transdermal patch products. The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003- 04.
Read also: Zydus Pharma gets USFDA nod for Eluxadoline Tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.